Transient vinblastine‐induced thrombocytopenia during chemotherapy with vinblastine, cis‐platinum and bleomycin

Arne Foss Abrahamsen, Olbjørn Klepp, Sophie D. Fossa, Anne Sønstevold

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

An early, transient drop in peripheral blood platelets to a mean nadir value of 49% (range 31–83%) of the pretreatment value was seen in 31 patients during chemotherapy with cis‐platinum, vinblastine and bleomycin (PVB). The mean number of platelets dropped by 22% during the first 24 h after the start of chemotherapy, nadir value was seen after 3 d, with recovery to 107% of pretreatment level on d 14–15. Platelet survival studies during PVB chemotherapy showed shortened platelet survival time and indicated increased destruction of platelets. Identical patterns of early, transient thrombocytopenia were seen in 6 patients treated with vinblastine only. The early fall in circulating platelets did not predict subsequent serious thrombocytopenia. There were no bleeding episodes in the 37 patients studied here, but the early thrombocytopenia seen after vinblastine therapy may possibly be of clinical importance in critically ill patients at risk for bleeding episodes. In rats, an early drop in circulating platelets occurred after a high dose of vinblastine, but not after bleomycin. Addition of bleomycin to vinblastine did not increase the vinblastine‐induced thrombocytopenia. It is concluded that the early drop in peripheral blood platelets during chemotherapy with PVB is due to vinblastine.

Original languageEnglish (US)
Pages (from-to)44-49
Number of pages6
JournalScandinavian Journal of Haematology
Volume37
Issue number1
DOIs
StatePublished - Jan 1 1986

Fingerprint

Vinblastine
Bleomycin
Thrombocytopenia
Blood Platelets
Drug Therapy
Hemorrhage
Platelet Count
Critical Illness

Keywords

  • bleomycin
  • cis‐platinum
  • thrombocyte survival
  • thrombocytopenia
  • vinblastine

ASJC Scopus subject areas

  • Hematology

Cite this

Transient vinblastine‐induced thrombocytopenia during chemotherapy with vinblastine, cis‐platinum and bleomycin. / Abrahamsen, Arne Foss; Klepp, Olbjørn; Fossa, Sophie D.; Sønstevold, Anne.

In: Scandinavian Journal of Haematology, Vol. 37, No. 1, 01.01.1986, p. 44-49.

Research output: Contribution to journalArticle

@article{eb8f354e0c124c1e9866564cf0beca00,
title = "Transient vinblastine‐induced thrombocytopenia during chemotherapy with vinblastine, cis‐platinum and bleomycin",
abstract = "An early, transient drop in peripheral blood platelets to a mean nadir value of 49{\%} (range 31–83{\%}) of the pretreatment value was seen in 31 patients during chemotherapy with cis‐platinum, vinblastine and bleomycin (PVB). The mean number of platelets dropped by 22{\%} during the first 24 h after the start of chemotherapy, nadir value was seen after 3 d, with recovery to 107{\%} of pretreatment level on d 14–15. Platelet survival studies during PVB chemotherapy showed shortened platelet survival time and indicated increased destruction of platelets. Identical patterns of early, transient thrombocytopenia were seen in 6 patients treated with vinblastine only. The early fall in circulating platelets did not predict subsequent serious thrombocytopenia. There were no bleeding episodes in the 37 patients studied here, but the early thrombocytopenia seen after vinblastine therapy may possibly be of clinical importance in critically ill patients at risk for bleeding episodes. In rats, an early drop in circulating platelets occurred after a high dose of vinblastine, but not after bleomycin. Addition of bleomycin to vinblastine did not increase the vinblastine‐induced thrombocytopenia. It is concluded that the early drop in peripheral blood platelets during chemotherapy with PVB is due to vinblastine.",
keywords = "bleomycin, cis‐platinum, thrombocyte survival, thrombocytopenia, vinblastine",
author = "Abrahamsen, {Arne Foss} and Olbj{\o}rn Klepp and Fossa, {Sophie D.} and Anne S{\o}nstevold",
year = "1986",
month = "1",
day = "1",
doi = "10.1111/j.1600-0609.1986.tb01770.x",
language = "English (US)",
volume = "37",
pages = "44--49",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Transient vinblastine‐induced thrombocytopenia during chemotherapy with vinblastine, cis‐platinum and bleomycin

AU - Abrahamsen, Arne Foss

AU - Klepp, Olbjørn

AU - Fossa, Sophie D.

AU - Sønstevold, Anne

PY - 1986/1/1

Y1 - 1986/1/1

N2 - An early, transient drop in peripheral blood platelets to a mean nadir value of 49% (range 31–83%) of the pretreatment value was seen in 31 patients during chemotherapy with cis‐platinum, vinblastine and bleomycin (PVB). The mean number of platelets dropped by 22% during the first 24 h after the start of chemotherapy, nadir value was seen after 3 d, with recovery to 107% of pretreatment level on d 14–15. Platelet survival studies during PVB chemotherapy showed shortened platelet survival time and indicated increased destruction of platelets. Identical patterns of early, transient thrombocytopenia were seen in 6 patients treated with vinblastine only. The early fall in circulating platelets did not predict subsequent serious thrombocytopenia. There were no bleeding episodes in the 37 patients studied here, but the early thrombocytopenia seen after vinblastine therapy may possibly be of clinical importance in critically ill patients at risk for bleeding episodes. In rats, an early drop in circulating platelets occurred after a high dose of vinblastine, but not after bleomycin. Addition of bleomycin to vinblastine did not increase the vinblastine‐induced thrombocytopenia. It is concluded that the early drop in peripheral blood platelets during chemotherapy with PVB is due to vinblastine.

AB - An early, transient drop in peripheral blood platelets to a mean nadir value of 49% (range 31–83%) of the pretreatment value was seen in 31 patients during chemotherapy with cis‐platinum, vinblastine and bleomycin (PVB). The mean number of platelets dropped by 22% during the first 24 h after the start of chemotherapy, nadir value was seen after 3 d, with recovery to 107% of pretreatment level on d 14–15. Platelet survival studies during PVB chemotherapy showed shortened platelet survival time and indicated increased destruction of platelets. Identical patterns of early, transient thrombocytopenia were seen in 6 patients treated with vinblastine only. The early fall in circulating platelets did not predict subsequent serious thrombocytopenia. There were no bleeding episodes in the 37 patients studied here, but the early thrombocytopenia seen after vinblastine therapy may possibly be of clinical importance in critically ill patients at risk for bleeding episodes. In rats, an early drop in circulating platelets occurred after a high dose of vinblastine, but not after bleomycin. Addition of bleomycin to vinblastine did not increase the vinblastine‐induced thrombocytopenia. It is concluded that the early drop in peripheral blood platelets during chemotherapy with PVB is due to vinblastine.

KW - bleomycin

KW - cis‐platinum

KW - thrombocyte survival

KW - thrombocytopenia

KW - vinblastine

UR - http://www.scopus.com/inward/record.url?scp=0022450437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022450437&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.1986.tb01770.x

DO - 10.1111/j.1600-0609.1986.tb01770.x

M3 - Article

C2 - 2429363

AN - SCOPUS:0022450437

VL - 37

SP - 44

EP - 49

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 1

ER -